Valued at USD 8.63 billion in 2024, the pruritus therapeutics market is projected to reach USD 8.97 billion in 2025 and USD 12.61 billion by 2034, growing at a CAGR of 5.50% during the forecast period 2025–2034. Major players include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb, Cara Therapeutics, GSK plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Pruritus therapeutics encompass treatments designed to alleviate pruritus, the medical term for chronic itching, which can accompany dermatological diseases such as eczema and psoriasis, systemic disorders including chronic kidney or liver disease, allergies, and even certain cancers. Growth is supported by the rising prevalence of skin conditions and chronic diseases that cause itching.

Disease Type Dynamics in the Pruritus Therapeutics Market

By disease type, the market is segmented into allergic contact dermatitis, atopic dermatitis, urticaria, and others. Atopic dermatitis dominated in 2024 owing to the high prevalence and chronic nature of the condition, which often includes severe and persistent itching as a primary symptom. The condition affects both children and adults, and its complexity necessitates ongoing treatment, driving continuous demand for therapeutic interventions.

Advances in understanding the immunological and genetic underpinnings of atopic dermatitis have spurred targeted therapies, including new biologics designed specifically to alleviate itching. These options offer improved efficacy and safety profiles, encouraging wider adoption among healthcare providers and patients. In February 2024, Galderma announced that the US FDA had accepted its Biologics License Applications for nemolizumab, for prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/global-pruritus-therapeutics-market

Product Insights: Why Corticosteroids Lead

By product, the market spans antihistamines, calcineurin inhibitors, corticosteroids, counterirritants, immunosuppressants, local anesthetics, and others. Corticosteroids held the dominant revenue share in 2024 because of their widespread use and proven efficacy against inflammatory skin conditions that cause itching. They are commonly prescribed first-line for eczema, psoriasis, and atopic dermatitis, since they effectively reduce inflammation and itching, and their availability in multiple formulations and systemic forms allows treatment to be tailored to severity and location.

Corticosteroids have been established in clinical practice for decades, building trust among providers and patients. Despite potential side effects with long-term use, rapid symptom relief and cost-effectiveness keep them a mainstay of pruritus management. Meanwhile, calcineurin inhibitors remain an important non-steroidal option within the broader product mix.

Demand Drivers and Restraints

Increasing prevalence of dermatological conditions is a significant driver. Urbanization, pollution, and changing lifestyles contribute to skin barrier dysfunction and immune system alterations, making eczema, psoriasis, and other inflammatory skin diseases more common. Rising awareness of the effect of chronic pruritus on quality of life is increasing demand for effective options, and the aging global population, which is more susceptible to conditions causing chronic itching, adds further momentum. Innovations in pharmaceuticals, particularly novel biologics and targeted therapies, are expanding the treatment arsenal and improving patient outcomes.

Two restraints deserve attention. First, the high cost of advanced treatments, particularly biologics, limits accessibility and adoption in developing regions with constrained healthcare budgets. Second, adverse effects and safety concerns, including immune suppression, increased susceptibility to infections, and liver or kidney damage associated with systemic medications, can lead to discontinuation and reduce patient compliance.

Regional Outlook

North America dominated the market, contributing over 36% share in 2023, supported by a high prevalence of atopic dermatitis, psoriasis, and eczema, advanced healthcare infrastructure, substantial healthcare expenditure, and extensive insurance coverage. The region also hosts leading pharmaceutical companies and research institutions developing new therapies. Asia Pacific is anticipated to grow substantially as urbanization and industrialization in China, India, and Japan raise the incidence of skin disorders, while economic growth increases healthcare spending and access to advanced medical therapies. For B2B stakeholders, the pruritus therapeutics market rewards portfolios that balance established corticosteroids with differentiated, better-tolerated innovation.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market